Sinco Pharma Sustainability Profile
Sinco Pharma, a leading player in the pharmaceutical industry, is headquartered in China (CN) and operates extensively across Asia and beyond. Founded in 2002, the company has established itself as a key provider of high-quality pharmaceutical products, specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. With a commitment to innovation and quality, Sinco Pharma offers a diverse range of products, including generic medications and custom synthesis services, which are distinguished by their rigorous quality control and compliance with international standards. The company has achieved significant milestones, including certifications from major regulatory bodies, solidifying its market position as a trusted supplier in the global pharmaceutical landscape. Sinco Pharma continues to expand its reach, driven by a dedication to enhancing healthcare outcomes worldwide.
DitchCarbon Score
How does Sinco Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sinco Pharma's score of 37 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sinco Pharma's reported carbon emissions
In 2022, Sinco Pharma reported total carbon emissions of approximately 1,000,850 kg CO2e, comprising Scope 1 emissions of about 645,260 kg CO2e and Scope 2 emissions of approximately 171,420 kg CO2e. Additionally, Scope 3 emissions from business travel and waste generated in operations amounted to about 64,170 kg CO2e and 2,860 kg CO2e, respectively. Sinco Pharma has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 CO2e emissions by 55% by 2030, compared to 2019 levels. This target reflects a significant effort to decrease the carbon footprint of its industrial operations. Furthermore, the company has pledged to achieve Net Zero emissions across all scopes before 2050. The emissions data reported by Sinco Pharma is cascaded from its parent company, Sinco Pharmaceuticals Holdings Limited, indicating a corporate family relationship that influences its sustainability initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 645,260 |
| Scope 2 | 171,420 |
| Scope 3 | 67,030 |
How Carbon Intensive is Sinco Pharma's Industry?
How Carbon Intensive is Sinco Pharma's Location?
Sinco Pharma's Scope 3 Categories Breakdown
Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 8% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 96% of Scope 3 emissions.
Top Scope 3 Categories
Sinco Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sinco Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
